July 20, 2023 03:09 PM EDT

FTC cautions against relying on its past PBM advocacy as industry pushes back

Lia DeGroot

The FTC on Thursday cautioned pharmacy benefit managers against relying on the agency’s previous statements and studies in support of PBMs, the middlemen who negotiate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC cautions against relying on its past PBM advocacy as industry pushes back

Lia DeGroot

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

FTC cau­tions against re­ly­ing on its past PBM ad­vo­ca­cy as in­dus­try push­es back

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FTC cautions against relying on its past PBM advocacy as industry pushes back